Nippon Chemiphar reported interim results for the fiscal year ending March 2027 on 30 October, with an ordinary loss of ¥684 million. The full-year forecast announced the same day remained unchanged from the previous forecast at ¥100 million.
Nippon Chemiphar announced its interim results for the fiscal year ending March 2027 on 30 October. Ordinary profit/loss was an ordinary loss of ¥684 million.
In its earnings forecast announced the same day, the company projected full-year ordinary profit of ¥100 million, unchanged from its previous forecast. The full-year forecast represents an expected decline in profit of approximately 55.9% from the previous forecast.
The article lists BrightPath Biotherapeutics Co., Ltd., Kubota Pharmaceutical Holdings Co., Ltd., Zeria Pharmaceutical Co., Ltd. and Seikagaku Corporation, among others, as related stocks, but provides no additional information on their performance.